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ABSTRACT  
Objectives: The aim of this study was to demonstrate the relationships between anti-citrullinated peptide/protein antibodies status and 
clinical characteristics, disease severity, radiological damages and laboratory assessment in Algerian patients with Rheumatoid arthritis, as well 
as their importance like a predictive factor for the diagnosis of Rheumatoid arthritis (RA). 
Methods: 281 patients diagnosed with RA according to ACR 1987 criteria in the  internal medicine and Functional Rehabilitation departments 
(the University Hospital of Sidi Bel Abbes) were enrolled in the study based on medical records including age, gender, disease duration, disease 
activity score (DAS28), joint damages, laboratory tests and treatment. All data were processed and analyzed via SPSS 22.0. 
Results: 86.5% of patients were females with a mean age and disease duration of respectively 52.665±12.3477, 4.19±4.050.  Patients with Anti-
CCP positive (79.7%) presented a high disease activity (p<0.0001), a long disease duration (p=0.016) and a erosion damages (p<0.0001). we 
did not found any significant relation between gender, hands damages and CRP..A logistic regression showed that the presence of Anti-CCP was 
associated with Erosion, disease activity, age and RF presence. 
Conclusion: There was a strong relation between Anti-CCP antibodies status and the development of RA in Algerian patients. It could be 
considered as a useful predictor of disease severity. 
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INTRODUCTION: 
Rheumatoid arthritis (RA) is a chronic inflammatory joint 
disease and sometimes extra-articular, characterized by 
irreversible destruction of joints and bones, disability and los 
of function 1-2-3. With a prevalence of 0.5% among adults in 
Western countries, and 0.13% in north Africa (Algeria in 
particular)4-5, reliable clinical research with the use of 
specific tests would be very useful for the early diagnosis of 
rheumatoid arthritis and therapeutic protocol6. 
Several studies prove that anti-CCP (anti-citrullinated 
peptide/protein antibodies) and Rheumatoid Factors (RF), 
have been regarded as major factors in joint destruction7. 
Anti-CCP is a more specific marker compared to RF, due to 
their high specificity to RA 8. 
Recently, the Anti-CCP became a major test of disease course, 
joints erosion, severity and early diagnosis9-10-11. It may be 
detectable before the onset of RA symptoms12, which proves 
their importance in the pathophysiology of 
RA13.Furthermore, Anti-CCP antibodies has been involved in 
criteria for ACR/EURL 2010 classification (the American 
College of Rheumatology/European League Against 
Rheumatism)14 
The aim of this study was to investigate Anti-CCP status in 
western Algeria population and their association with 
clinical feature and medical managements (Disease activity, 
radiographic damages, erosion …) of Algerian patients with 
RA.as well as their importance in the diagnosis of RA. 
PATIENTS AND METHODS: 
The population: 
We carried out a cross study based on medical records over 
281 patients with RA aged of 14 years or over; diagnosed 
between 2016 and 2019 at the level of Internal Medicine in 
partnership with Functional Rehabilitation Departments of 
the University Hospital of Sidi Bel Abbes. 
Patients were diagnosed according to ACR 1987 criteria 15. 
The local Ethics Committee of University Hospital has 
approved our study. 
We recorded the demographic characteristic such as: sex, 
age; and clinical and managements like: Disease duration, 
Disease activity score (DAS28) (running from 0 to 10), 
Erosion, Radiologic Joint damage, Laboratory assessment 
and Medication. 
Concerning DAS28, the threshold values are over 5.1 for high 
activity, from 5.1 to 3.2 for moderate activity, between 3.2 
and 2.6 for low activity and less than 2.6 for remission 16. 
Statistical Analysis: 
Patients' characteristics were presented as means and 
standard deviation for continuous variables and as 
frequencies and percentages for categorical variables. 
For descriptive analysis we present the results as 
Mean±standard deviation and frequency (%). For the cross 
study, the categorical variables were tested using Pearson’s 
Khi2 test (χ
2
) and T test for continuous variables. Logistic 
regression was used to estimate the independent effects of 
some RA characteristics on the presence of anti-CCP. 
All data were processed and analyzed via SPSS 22.0 
(Statistical Package for the Social Sciences, IBM 
Corporation; Chicago, IL. August 2013).The level of 
significance was <5% 
RESULTS: 
A total of 281 patients with rheumatoid arthritis were 
included in our cross study (86.5% were women ; 
females/males ratio 7.3947 ), the mean age was of 
52.665±12.3477 ( range 14-80); The most affected age group 
was ≥46 years with a rate of 74.4%, 8.2% of males were 
smokers, More than half of our patients were affected in 
hands joints (68.3%) followed by wrists (60.1%).The mean 
disease duration and DAS28 of the enrolled participants 
were 4.19±4.050 and 4.5128±1.23452 respectively. 
Concerning the disease activity, 1.1% of patients in the 
remission status, 13.5% with a low activity, 54.4% with a 
moderate activity and 31% with a high activity. Positive anti-
ccp and RF were noted in 79.7% and 80.4% of patients 
respectively (Table 1). 
Table 2 demonstrate a comparison of various factors such as 
gender; age; disease duration; erosion; tobacco status; joint 
damage; ESR; CRP and medication in two rheumatoid 
arthritis groups (positive and  negative Anti-CCP groups).We 
noted a high signification between the erosion; DAS 28,high 
activity ; shoulders joints  and the positive Anti-CCP group 
(p=<0.0001). We reported also a signification between Anti-
CCp status and tobacco (p=0.047), ESR (p=0.001), 
Methotrexate use (p=0.003). 
Table 03 indicates an analysis of the characteristics of RA 
such as age; DAS28, joint damage, erosion, ESR in accordance 
with RF and Anti-CCP status. 
We noticed a mutual association of Anti-CCP rate with DAS28 
(Figure 1) and Disease duration (Figure 2) 
The Binary logistic regression illustrated that the Anti-CCP 
status was significantly associated with age; disease 
duration; DAS28; ESR and RF (Table 4). 
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Figure 1: linear correlation between Anti-CCP titer and disease activity score (DAS28) 
 
 
Figure 2: linear correlation between Anti-CCP titer and Disease duration 
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Table 1 : Charactéristics of RA patients 
Characteristics (Mean±SD) or n(%) Rheumatoid arthritis n=281 
Female gender  243(86.5%) 
Age (years) 
≤ 45  
≥46 
52.665±12.3477 
72(25.6%) 
209(74.4%) 
Disease duration (years) 4.19±4.050 
Comorbidity 
Type 2 diabetes 
Hypertension 
 
40(14.2%) 
114(40.6%) 
active tobacco (males) 23(8.2%) 
Radiologic Joint damage 
Hands 
Wrists 
Knees 
Elbows 
Shoulders 
Feet 
Ankle 
 
192(68.3%) 
169(60.1%) 
158(56.2%) 
109(38.8%) 
100(35.6%) 
86(30.6%) 
44(15.7%) 
Erosion 67(23.8%) 
DAS28 4.5128±1.23452 
Disease activity 
Remission 
Low 
Moderate 
High 
 
3(1.1%) 
38(13.5%) 
153(54.4%) 
87(31%) 
Anti-CCP titer (Ul/ml) 191.1977±164.87025 
Positive Anti-CCP 224(79.7%) 
RF titer (Ul/ml) 68.5438±76.30074 
Positive RF 226(80.4%) 
ESR titer (mm/h) 43.434±24.8095 
Accelerated ESR 230(81.9%) 
CRP titer 17.9390±28.69422 
Positive CRP 184(65.5%) 
Medication 
Methotrexate 
leflunomide 
Hydroxychloroquine 
Glucocorticoid 
 
226(80.4%) 
45(16%) 
4(1.4%) 
159(56.6%) 
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Table 2: Data based on Anti-CCP status in RA patients 
Characteristics n(%) RA patients n=281  
P value Positive Anti-CCP  
n=224 
Negative Anti-CCP  
n=57 
Female gender  32(11.39%) 6(2.14%) 0.459 
Age (years) 51.192±12.940 58.456±11.2870 <0.0001 
Disease duration (years) 4.48±4.280 3.04±2.712 0.016 
Erosion 64(22.78%) 3(1.07%) <0.0001 
Active tobacco (males) 22(7.83%) 1(0.36%) 0.047 
Disease activity 
Remission 
Low 
Moderate 
High 
 
1(0.36%) 
18(6.41%) 
123(43.77%) 
82(29.18%) 
 
2(0.71%) 
20(7.12%) 
30(10.68%) 
5(1.78%) 
 
0.045 
<0.0001 
0.758 
<0.0001 
DAS28 4.7166±1.19056 3.7119±1.07554 <0.0001 
Joint damage 
Hands 
Wrists 
Knees 
Elbows 
Shoulders 
Feet 
Ankle 
 
158(56.23%) 
144(51.25%) 
126(44.84%) 
94(33.45%) 
93(33.10%) 
71(25.27%) 
39(13.88%) 
 
34(12.10%) 
25(8.90%) 
32(11.39%) 
15(5.34%) 
7(2.49%) 
15(5.34%) 
5(1.78%) 
 
0.115 
0.005 
0.988 
0.030 
<0.0001 
0.431 
0.109 
Laboratory assessment     
ESR(mm/h) 45.875±25.0779 33.842±21.3473 0.001 
CRP (Ul/ml) 19.0826±31.27544 13.4451±13.99490 0.186 
Drugs use 
Methotrexate  
leflunomide  
Hydroxychloroquine  
Glucocorticoid 
 
188(66.90%) 
35(12.46%) 
3(1.07%) 
132(46.98%) 
 
38(13.52%) 
10(3.56%) 
1(0.36%) 
27(9.61%) 
 
0.003 
0.724 
0.813 
0.116 
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Table 3: Charactiristics of RA patients according to Anti-CCP and RF status. 
Characteristics 
n(%)/(Mean±SD) 
RA patients n=281  
P value 
Anti-CCP- FR- 
N=55 
Anti-CCP- FR+ 
N=2 
Anti-CCP+ RF+ 
N=224 
Female gender 50(17.79%) 1(0.36%) 192(68.33%) 0.191 
Age (years) 
≤ 45  
≥46 
 
6(2.14%) 
49(17.44%) 
 
00 
2(0.71%) 
 
66(23.49%) 
158(56.23%) 
 
0.013 
Disease duration (years) 
˂4 
5-11 
12-18 
˃18 
 
41(14.59%) 
13(4.63%) 
1(0.36) 
00 
 
1(0.36%) 
1(0.36%) 
00 
00 
 
124(44.13%) 
86(30.60%) 
5(1.78%) 
9(3.20%) 
 
0.033 
0.112 
0.961 
0.306 
Erosion 2(0.71%) 1(0.36%) 64(22.78%) <0.0001 
Active tobacco(males) 00 1(0.36%) 22(7.83) 0.006 
Disease activity 
Remission 
Low 
Moderate 
High 
 
2(0.71%) 
20(7.12%) 
28(9.96%) 
5(1.78%) 
 
00 
00 
2(0.71%) 
00 
 
1(0.36%) 
18(6.41%) 
123 
82(29.18%) 
 
0.118 
<0.0001 
0.373 
<0.0001 
Joint damage 
Hands 
Wrists 
Knees 
Elbows 
Shoulders 
Feet 
Ankle 
 
33(11.74%) 
23(8.19%) 
31(11.03%) 
14(4.98%) 
6(2.14%) 
14(4.98%) 
4(1.42%) 
 
1(0.36%) 
2(0.71%) 
1(0.36%) 
1(0.36%) 
1(0.36%) 
1(0.36%) 
1(0.36%) 
 
158(56.23%) 
144(51.25%) 
126(44.84%) 
94(33.45%) 
93(33.10%) 
71(25.27%) 
39(13.88%) 
 
0.276 
0.005 
0.948 
0.075 
<0.0001 
0.558 
0.073 
Accelerated ESR 39(13.88%) 2(0.71%) 189(6.26%) 0.054 
Positive CRP 32(11.39%) 1(0.36%) 151(53.74%) 0.391 
Methotrexate intake  36(12.81%) 2(0.71%) 188(66.90%) 0.007 
 
Table 4: Binary regression for the presence of Anti-CCP 
Factors RA Patients n= 281 
OR 95% IC P value 
Age (years) 0.945 0,919-0.973 <0.0001 
Disease duration (years) 1.159 1.023-1.313 0.021 
DAS28 2.230 1.648-3.017 <0.0001 
ESR(mm/h) 1.024 1.009-1.039 0.001 
CRP (Ul/ml) 1.014 0.995-1.034 0.146 
RF  (Ul/ml) 1.158 1.112-1.206 <0.0001 
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DISCUSSION: 
Positive anti-CCP status is primarily associated with bone 
loss, disability, disease duration and disease activity in RA 
patients 17. Our cross study showed this relationship 
between clinical characteristics, disease activity, joints 
damages and Anti-CCP status in Algerian RA patient from 
western Algeria (Sidi Bel Abbes region in particular ). 
BARRA.L et al illustrated that positive Anti-CCP group were 
younger (p<0.0001) with a longer disease duration 18. 
Moreover, ARNAB.B et al, reported a similar results 
regarding the duration of the disease and Anti-CCP (p=0.003) 
19. Orsolini. G et al 20 reported as well a correlation between 
disease duration and Anti-CCP status (p=0.014). Anti-CCP 
negative patients were older with less disease activity 21. 
There is a strong association between anti-CCPs and 
radiological joints damages 22. Ghozlani et al 23 confirm the 
influence of anti-CCPs status on radiological erosion 
(p=0.001). Furthermore. Yang et al24 noted a high correlation 
between Anti-CCP positive and sever joint 
damage(<0.005).Another study by Im et al13 showed a 
significant association between erosion and Anti-CCP 
positive (p=0.0024). Barra et al 18 conclude the same result 
in 160 patients (p=0.0058). However, the results of Slimani 
et al 21 disagreed with previous investigations, they did not 
find any relation between erosion and Anti-CCP status. 
In RA there is a significant association between RF, anti-ccp 
and disease severity 23-25. However, patients positive for anti-
CCPand RF both had a high risk of disease progression 26. In 
addition, Forslind et al.22 show that anti-CCP appeared to be 
an important predictor in early RA. Nonetheless, Barra et al 
18 did not find any significant association between RF 
positivity and erosive disease. 
A significant relation between radiologic assessment of wrist, 
hands and positive Anti-CCP was observed in the Serdaroğlu 
et al data27. In our investigation we found a significant 
correlation between wrist radiologic damages and positive 
Anti-CCP patients (p=0.005) 
According to another investigation 28-29-30-31. Our study 
demonstrate a high association between Anti-CCP status and 
DAS28 (p<0.0001). These results were in contradiction with 
some studies from Tunisia, Thailand, Egypt and Italy 25-30-32-
20. 
There was no significant correlation between the analyses of 
laboratory assessment and positive Anti-CCP23-33-18-27, many 
studies disagreed with this investigation19-21-22-34-35, they 
found a high significant relation between ESR and Anti-CCP 
status similar to our results (p=0.001). 
Smoking increases the high secretion of anti-CCP antibodies 
in RA patients with shared epitope36-37. Forslind et al 22, 
García de Veas Silva et al 38 reported a high significant 
association between Anti-CCP status and smoking. Our data 
demonstrate a significant association (p=0.047). Other 
studies 18-20 were paradoxical with previous results that 
showed no significant difference between tobacco status and 
positive Anti-CCP. 
Likewise, The most common received drug in our data was 
Methotrexate with a significant different with Positive Anti-
CCP patients (p=0.003).Nevertheless, some studies did not 
find any correlation between Methorexate use and Anti-CCP 
positive 18-21 
CONCLUSION: 
Our data showed that Algerian RA patients with positive 
Anti-CCP antibodies have an active high disease activity and 
long disease duration. Anti-CCP was considered as a 
predicator factor for, radiologic erosion joint progression 
and as prognostic factor of RA to predict the course of 
disease activity and the effectiveness of the treatment. 
Further studies on larger numbers of patients are needed to 
confirm our findings. 
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